Butler Casey Scott
Pain Medicine, Mayo Clinic Health System, Eau Claire, WI.
Pain Med Case Rep. 2024 Nov;8(7):253-256.
Post-COVID-19 neuropathic pain is a difficult-to-treat condition seen in approximately one-third of patients with long COVID. It has been shown to be resistant to many first-line therapies as well as over-the-counter and prescription medications.
We present the case of a 27-year-old man who developed bilateral upper extremity neuropathic pain in conjunction with a severe COVID-19 infection. He failed occupational therapy, multiple medications, and a stellate ganglion block. A dorsal column stimulator was placed and provided the patient with both pain relief and improved functionality.
Given the results of this case and the history of neuromodulation in effectively treating neuropathic pain, we submit that neuromodulation is a viable option for patients with refractory post-COVID-19 neuropathic pain.
新冠后神经病理性疼痛是一种难以治疗的病症，在大约三分之一的长期新冠患者中可见。已证明它对许多一线疗法以及非处方和处方药均有耐药性。
我们报告一例27岁男性病例，该患者在感染严重新冠病毒的同时出现双侧上肢神经病理性疼痛。他接受职业治疗、多种药物治疗以及星状神经节阻滞均无效。植入了背柱刺激器，患者的疼痛得到缓解，功能也有所改善。
鉴于该病例的结果以及神经调节在有效治疗神经病理性疼痛方面的历史，我们认为神经调节是治疗难治性新冠后神经病理性疼痛患者的一种可行选择。
